0
Argentina ha aprobado Agalzyme, un biosimilar de la agalsidasa beta, como la primera terapia de reemplazo enzimático para la enfermedad de Fabry en América Latina, lo que representa un importante a...
More >- INICIO
-
Genéricos
Novedades
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Investigación
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
General
- Crecimiento de medicamentos genéricos en Brasil y Venezuela
- EMA launches European shortages monitoring platform to tackle persistent medicine shortages
- Penetración de los medicamentos genéricos en México y Brasil
- FDA releases one-year progress report for the Generic Drug Cluster
-
Biosimilares
Novedades
- Argentina aprueba el primer biosimilar de agalsidasa beta para la enfermedad de Fabry
- Hulio granted US interchangeability status
- Primer medicamento biológico similar de pembrolizumab introducido en Paraguay
- UK MHRA approves biosimilars Zefylti (filgrastim) and Ahzantive (aflibercept)
- MORE EDITORIAL SECTIONS
- Search
